FY2028 EPS Estimates for CapsoVision Cut by Roth Capital

Key Points

• Roth Capital has revised its earnings estimates for CapsoVision, lowering the FY2028 EPS forecast from $0.35 to $0.33, while maintaining a "Strong-Buy" rating and a target price of $6.00.
• In their latest earnings report, CapsoVision reported an EPS of ($2.02), significantly missing analyst expectations of ($0.11).
• Other analysts have varied opinions on CapsoVision, with Wall Street Zen upgrading it to a "hold" rating and Benchmark initiating coverage with a "speculative buy" rating and a $5.00 price target.

CapsoVision, Inc. (NASDAQ:CV - Free Report) - Analysts at Roth Capital lowered their FY2028 earnings estimates for CapsoVision in a research note issued on Thursday, August 14th. Roth Capital analyst J. Wittes now forecasts that the company will post earnings of $0.33 per share for the year, down from their previous forecast of $0.35. Roth Capital has a "Strong-Buy" rating and a $6.00 price objective on the stock. Roth Capital also issued estimates for CapsoVision's FY2029 earnings at $0.54 EPS.

Several other equities research analysts have also issued reports on the stock. Benchmark initiated coverage on shares of CapsoVision in a research report on Monday, July 28th. They set a "speculative buy" rating and a $5.00 target price for the company. Wall Street Zen upgraded shares of CapsoVision to a "hold" rating in a report on Sunday, July 13th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Strong Buy" and a consensus price target of $5.50.

CapsoVision Trading Down 0.8%

CapsoVision stock traded down $0.03 during mid-day trading on Monday, hitting $3.95. 13,163 shares of the company traded hands, compared to its average volume of 270,553. CapsoVision has a one year low of $3.49 and a one year high of $5.72.

CapsoVision (NASDAQ:CV - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported ($2.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($1.91). The business had revenue of $3.32 million for the quarter, compared to analyst estimates of $3.20 million.

About CapsoVision

We are a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) technologies that are deployed in our capsule endoscopy solutions to identify abnormalities of the gastrointestinal (“GI”) tract for diagnostic and screening purposes. We developed our first capsule endoscope system, currently comprising the CapsoCam Plus single-usecapsule and the CapsoCloud and CapsoView software, to panoramically visualize the small-bowel mucosa to investigate abnormalities such as obscure GI bleeding and Crohn's disease.